Inicio › Leucemia linfocítica crónica › Washington › Seattle
Ensayos clínicos de Leucemia linfocítica crónica en Seattle, WA
22 estudios para Leucemia linfocítica crónica buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ReclutandoFase 3
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- y 1 más
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- y 1 más
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ReclutandoFase 3
- Swedish Medical Center-First Hill, Seattle
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
ReclutandoFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
ReclutandoFase 3
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
ReclutandoFase 1
- Fred Hutch Cancer Center, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
ReclutandoFase 3
- Swedish Medical Center-Swedish Cancer Institute ( Site 0071), Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
ReclutandoFase 1/2
- Research Site, Seattle
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ReclutandoFase 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ReclutandoFase 3
- Fred Hutchinson Cancer Research Center, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
ReclutandoFase 2Se aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Swedish Cancer Institute, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
ReclutandoFase 1
- Swedish Cancer Institute, Seattle
Ensayos de Leucemia linfocítica crónica en otras ciudades
- Boston, MA31 estudios
- Columbus, OH29 estudios
- Durham, NC28 estudios
- Washington, DC22 estudios
- Rochester, MN20 estudios
- New York City, NY20 estudios
- Houston, TX18 estudios
- Baldwin Park, CA18 estudios
- Cincinnati, OH15 estudios
- Milwaukee, WI15 estudios
- Chicago, IL14 estudios
- Nashville, TN13 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer (todos los tipos)48 estudios
- Cáncer de próstata45 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer metastásico39 estudios
- Cáncer de seno37 estudios
- Cáncer del colon y del recto35 estudios
- Cáncer de pulmón34 estudios
- Cáncer de ovario29 estudios
- Cáncer de páncreas22 estudios
- Mieloma múltiple22 estudios
- Leucemia linfoblástica aguda22 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.